Amgen And ShanghaiTech University announce plans for R&D center
25 September 2013 | By Amgen
Amgen And ShanghaiTech University agree plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University...
List view / Grid view
News
Pfizer announces data for XELJANZ® (tofacitinib citrate) in rheumatoid arthritis
25 September 2013 | By Pfizer
Long-term safety and efficacy data of XELJANZ up to five years will be presented at the American College Of Rheumatology 2013 annual meeting...
AbbVie and Galapagos to co-develop Cystic Fibrosis therapies
25 September 2013 | By AbbVie
Global alliance formed to discover, develop and commercialise novel potentiator and combination therapies in cystic fibrosis...
Latest Phase 3 Results demonstrate safety profile of INVOKANA® (canagliflozin) as add-on therapy in the treatment of Type 2 Diabetes
24 September 2013 | By Janssen Research & Development, LLC
In patients inadequately controlled on metformin and a sulfonylurea, study results suggest canagliflozin improves glycemic control and was generally well tolerated, compared to placebo...
Data presented at EASD support safety profile of Trajenta® (linagliptin) in broad range of adults with Type 2 Diabetes
24 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented…
Takeda receives European marketing authorisation for three new type 2 diabetes therapies
24 September 2013 | By Takeda
Authorisation received for VipidiaTM (alogliptin) and Fixed-Dose Combinations VipdometTM (alogliptin and metformin) and IncresyncTM (alogliptin and pioglitazone)...
FDA imposes import ban on Ranbaxy’s Mohali plant
24 September 2013 | By Daiichi Sankyo Company, Limited
Ranbaxy Laboratories has received communication from the FDA about an Import Alert imposed on its Mohali, India, plant following an inspection in late 2012...
Paul Marks Prize 2013 awarded to Cancer Research UK scientist
23 September 2013 | By Cancer Research UK
Dr Simon Boulton has been named as one of the recipients of the 2013 Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center in America...
Teva announces favorable court ruling in AZILECT® patent infringement litigation against Mylan
23 September 2013 | By Teva
The Court has upheld the validity of Teva’s patent. Teva anticipates the Court will enter Judgment that prevents Mylan from launching its generic version of Azilect® until Teva’s patent expires in 2017.
Merck receives complete response letter for investigational medicine Sugammadex Sodium Injection
23 September 2013 | By Merck
Merck has received a Complete Response Letter from the FDA for the resubmission of the New Drug Application for sugammadex sodium injection, Merck’s investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or vecuronium...
Roche to share important oncology data at European Cancer Congress (ECC)
23 September 2013 | By Roche
Data for established therapies Avastin, Herceptin, Kadcyla and Zelboraf amongst highlights...
Biogen Idec to present extensive new data from its robust multiple sclerosis portfolio at ECTRIMS
23 September 2013 | By Biogen Idec
More than 55 company-sponsored presentations underscore Biogen Idec’s commitment to treatment advances for people with MS...
Ablynx And AbbVie sign global license agreement for anti-IL-6R nanobody, ALX-0061
23 September 2013 | By Abbvie
Anti-IL-6R Nanobody, ALX-0061, to be developed in rheumatoid arthritis and systemic lupus erythematosus...
Otsuka and Lundbeck receive positive CHMP opinion for Abilify Maintena(r) in schizophrenia
21 September 2013 | By
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation for the maintenance treatment of schizophrenia in adult patients stabilised…
NovoEight® (turoctocog alfa) receives positive opinion from the European regulatory authorities
20 September 2013 | By Novo Nordisk
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion on its recombinant factor VIII product turoctocog alfa, with the intended brand name NovoEight®...
